bendamustine hydrochloride has been researched along with fludarabine in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (13.56) | 29.6817 |
| 2010's | 38 (64.41) | 24.3611 |
| 2020's | 13 (22.03) | 2.80 |
| Authors | Studies |
|---|---|
| Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K | 1 |
| Bergmann, M; Emmerich, B; Fingerle-Rowson, G; Goede, V; Hallek, M; Schmitt, B; Schweighofer, C; Wendtner, CM | 1 |
| Assmann, M; Bartsch, R; Eschenburg, H; Franke, A; Herold, M; Jentsch-Ullrich, K; Kahl, C; Knauf, W; Koenigsmann, M; Lakner, V; Mohren, M; Müller, G; Pasold, R | 1 |
| Adam, K; Bergmann, J; Buchheidt, D; Hehlmann, R; Hummel, M; Reiter, S | 1 |
| Blau, IW; Busse, A; Knauf, W; Reufi, B; Schmidt-Hieber, M; Thiel, E | 1 |
| Cheson, BD | 1 |
| Alonso, R; Bantia, S; Bontemps, F; Campo, E; Colomer, D; López-Guerra, M; Manz, C; Mehrling, T; Montserrat, E; Smal, C; Upshaw, R; Villamor, N | 1 |
| Hallek, M | 1 |
| Giné, E; Gutiérrez-García, G; López-Guillermo, A | 1 |
| Brassac, M; Fournié, JJ; Gross, E; Kheirallah, S; L'Faqihi-Olive, FE; Laurent, G; Quillet-Mary, A; Struski, S; Ysebaert, L | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D | 1 |
| Balleisen, L; Eimermacher, H; Freier, W; Heit, W; Hinke, A; Ibach, S; Knauf, W; Megdenberg, D; Niederle, N; Weiß, J | 1 |
| Caimi, P; Habecker, B; Hill, BT; Kalaycio, M; Kindwall-Keller, T | 1 |
| Aoki, S | 1 |
| Abrisqueta, P; Bosch, F; Calpe, E; Carabia, J; Carpio, C; Castellví, J; Crespo, M; Palacio, C; Purroy, N | 1 |
| Abenhardt, W; Dörfel, S; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Meyer, D; Münz, M | 1 |
| Ayres, ML; Baladandayuthapani, V; El-Mabhouh, AA; Gandhi, V; Keating, MJ; Shpall, EJ; Wierda, WG | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W | 1 |
| Becker, HJ; Beckmann, L; Brinkmann, K; Fandrey, J; Frenzel, LP; Hallek, M; Huelsemann, MF; Kashkar, H; Otto, T; Pallasch, CP; Patz, M; Reinhardt, HC; Theurich, S; von Bergwelt-Baildon, M; Wendtner, CM; Zahedi, RP | 1 |
| Foltynski, P; Ladyzynski, P; Molik, M | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; Lymp, J; O'Brien, S; Pagel, JM | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Treon, SP | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Langerbeins, P | 1 |
| Jallad, B; Mawri, S; Nabi, S; Won, J | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
| Balser, C; Barth, J; Blau, W; Boeck, HP; Brugger, W; Hahn, L; Hinke, A; Kaiser, U; Kauff, F; Losem, C; Mueller, L; Niederle, N; Rummel, M; Sandherr, M; Stauch, M; Vereshchagina, J; von Gruenhagen, U; Weidmann, E; Welslau, M | 1 |
| Goto, H; Goto, S; Yokosuka, T | 1 |
| Böhme, A; Dreyling, M; Fries, S; Höhler, T; Kellermann, L; Kiewe, P; Zoellner, AK | 1 |
| Bahlo, J; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kovacs, G; Langerbeins, P; Maurer, C; Müller, L; Pflug, N; Ritgen, M; Seiler, T; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Bahlo, J; Böttcher, S; Busch, R; Döhner, H; Eichhorst, B; Fink, AM; Fischer, K; Gregor, M; Hallek, M; Kiehl, M; Klapper, W; Kneba, M; Köchling, G; Köppler, H; Kovacs, G; Kreuzer, KA; Lange, E; Maurer, C; Plesner, T; Plöger, C; Schlag, R; Sökler, M; Stilgenbauer, S; Trneny, M; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Altenhofer, P; Andel, J; Burcoveanu, C; Burgstaller, S; Doubek, M; Egle, A; Flochová, E; Fridrik, M; Gercheva, L; Girschikofsky, M; Greil, R; Hrubiško, M; Jäger, U; Klingler, A; Kozák, T; Králiková, E; Ladická, M; Mayer, J; Melchardt, T; Mihaylov, G; Mikušková, E; Nösslinger, T; Obrtlíková, P; Oexle, H; Palášthy, S; Papajík, T; Pecherstorfer, M; Petzer, A; Pleyer, L; Raynov, J; Smolej, L; Spasov, E; Stehlíková, O; Steurer, M; Zabernigg, A | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Ahmed, S; Alatrash, G; Anderlini, P; Bassett, RL; Burger, JA; Ciurea, SO; Ferrajoli, A; Gulbis, AM; Jabbour, EJ; Jorgensen, JL; Kadia, TM; Khouri, IF; Ledesma, C; Marin, D; Medeiros, LJ; Olson, A; Oran, B; Patel, KK; Popat, UR; Samuels, BI; Sui, D; Turturro, F | 1 |
| Allsup, D; Bloor, A; Collett, L; Hillmen, P; Hockaday, A; Howard, DR; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC | 1 |
| Ayres, ML; Balakrishnan, K; Burger, JA; Cortes, JE; Ferrajoli, A; Gandhi, V; Jain, N; Kadia, TM; Keating, MJ; O'Brien, SM; Tambaro, FP; Wierda, WG | 1 |
| Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S | 1 |
| Andersson, PO; Asklid, A; Bjellvi, J; Hansson, L; Johansson, H; Karlsson, C; Karlsson, K; Kimby, E; Klintman, J; Lauri, B; Mattsson, M; Norin, S; Österborg, A; Sandstedt, AB; Strandberg, M; Sylvan, SE; Tolvgård, S | 1 |
| Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; McIver, T; Morariu-Zamfir, R; O'Brien, S; Pagel, JM | 1 |
| Brychtova, Y; Brzobohata, A; Doubek, M; Mayer, J; Mraz, M; Panovska, A; Pavlova, S; Pospisilova, S; Skuhrova Francova, H; Spunarova, M; Tom, N; Trbusek, M | 1 |
| Facco, M; Frezzato, F; Gurrieri, C; Imbergamo, S; Martini, V; Pagnin, E; Piazza, F; Pravato, S; Raggi, F; Scomazzon, E; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A | 1 |
| Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
| Gordiienko, I; Ivanivska, T; Shcherbina, V; Shlapatska, L; Sidorenko, S | 1 |
| Bloehdorn, J; Döhner, H; Lichter, P; Mertens, D; Stilgenbauer, S; Yosifov, DY | 1 |
| Barcellini, W; Berentsen, S; Brudevold, R; D'Sa, S; Dahm, AEA; Dalgaard, J; Fattizzo, B; Frøen, H; Hallstensen, RF; Haukås, E; Hjorth-Hansen, H; Jæger, PH; Kell, M; Małecka, A; Oksman, M; Randen, U; Rolke, J; Sekhar, M; Sørbø, JH; Tjønnfjord, E; Tjønnfjord, GE; Tsykunova, G; Tvedt, THA | 1 |
| Beaven, AW; Brenner, MK; Buchanan, FB; Cheng, CJ; Dittus, C; Dotti, G; Eldridge, PW; Gee, AP; Grilley, BJ; Grover, NS; Heslop, HE; Ivanova, A; Lulla, PD; McKay, KL; Mehta, B; Morrison, K; Park, SI; Ramos, CA; Rooney, CM; Savoldo, B; Serody, JS; Shea, TC; Wang, T; Wu, MF | 1 |
| Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Allsup, D; Bloor, A; Emmerson, J; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Nathwani, A; Oughton, JB; Paneesha, S; Phillips, D; Rawstron, A; Turner, D | 1 |
| Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L | 1 |
| Böttcher, S; Decker, T; Eichhorst, B; Fink, AM; Fischer, K; Hallek, M; Heinisch, K; Holmes, EE; Kreuzer, KA; Kutsch, N; Müller-Hagen, S; Ritgen, M; Robrecht, S; Schüler, G; Stilgenbauer, S; Vehling-Kaiser, U; Wendtner, CM | 1 |
| Green, S; Schultz, L | 1 |
| Bahlo, J; Baumann, M; Brüggemann, M; Christiansen, I; da Cunha-Bang, C; De Silva, N; Eichhorst, B; Enggaard, L; Fink, AM; Fischer, K; Frederiksen, H; Fürstenau, M; Gaska, T; Geisler, C; Goede, J; Gregor, M; Hallek, M; Hebart, H; Hoogendoorn, M; Illmer, T; Jäger, U; Janssens, A; Juliusson, G; Kater, AP; Koene, H; Kreuzer, KA; Levin, MD; Leys, MBL; Lindström, V; Lotfi, K; Niemann, CU; Nösslinger, T; Poulsen, CB; Regelink, JC; Ritgen, M; Robrecht, S; Schneider, C; Schöttker, B; Simon, F; Staber, PB; Stilgenbauer, S; Tadmor, T; Tausch, E; Thornton, P; van der Klift, M; van Oers, M; von Tresckow, J; Wendtner, CM; Widmer, A; Zhang, C | 1 |
| Arai, S; Bharadwaj, S; Budde, LE; Dahiya, S; Frank, MJ; Goyal, A; Hosoya, H; Hovanky, V; Htut, M; Janakiram, M; Jensen, A; Latchford, T; Leahy, S; Liu, L; Mei, M; Miklos, D; Muffly, LS; Sahaf, B; Sidana, S | 1 |
13 review(s) available for bendamustine hydrochloride and fludarabine
| Article | Year |
|---|---|
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Combined Modality Therapy; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Time Factors; Vidarabine | 2003 |
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
State-of-the-art treatment of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Combined Modality Therapy; Cytostatic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Salvage Therapy; Thionucleotides; Transplantation, Homologous; Vidarabine | 2009 |
Current immunochemotherapy strategies in follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Nitrogen Mustard Compounds; Prednisone; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Vidarabine; Vincristine | 2010 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Nitrogen Mustard Compounds; Pentostatin; Physical Fitness; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2015 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Practice Guidelines as Topic; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
Topics: Bendamustine Hydrochloride; Burkitt Lymphoma; Child; Clofarabine; Cyclophosphamide; Humans; Immunotherapy, Adoptive; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Young Adult | 2023 |
18 trial(s) available for bendamustine hydrochloride and fludarabine
| Article | Year |
|---|---|
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
Topics: Adult; Aged; Bendamustine Hydrochloride; Female; Germany; Hematology; Humans; Lymphoma; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Societies, Medical; Time Factors; Vidarabine | 2004 |
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2011 |
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Survival Analysis; Treatment Outcome; Vidarabine | 2013 |
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2015 |
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2016 |
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Case-Control Studies; Cell Transformation, Neoplastic; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Registries; Risk Assessment; Risk Factors; Vidarabine | 2016 |
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; International Agencies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2016 |
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Survival Rate; Vidarabine | 2016 |
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Protocols; Cyclophosphamide; Drug Dosage Calculations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vidarabine | 2016 |
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine | 2017 |
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2018 |
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Registries; Retrospective Studies; Rituximab; Survival Rate; Sweden; Vidarabine | 2019 |
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Rituximab; Vidarabine | 2020 |
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Epitopes; Female; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Ki-1 Antigen; Lymphocyte Depletion; Male; Middle Aged; Stem Cell Transplantation; Vidarabine; Young Adult | 2020 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2021 |
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Rituximab | 2023 |
28 other study(ies) available for bendamustine hydrochloride and fludarabine
| Article | Year |
|---|---|
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine | 2002 |
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Creatinine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recombinant Proteins; Renal Insufficiency; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine | 2005 |
Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Blood Component Removal; Bone Marrow Cells; Cell Culture Techniques; Cell Survival; Colony-Forming Units Assay; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Models, Biological; Nitrogen Mustard Compounds; Reference Values; Stem Cells; Vidarabine | 2009 |
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bendamustine Hydrochloride; Cyclophosphamide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Mitochondria; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Purine Nucleosides; Pyrimidinones; Rituximab; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2009 |
B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Separation; Coloring Agents; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Phenotype; Recombinant Proteins; Rituximab; Vidarabine | 2010 |
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine | 2014 |
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Bone Marrow Cells; CD40 Antigens; Cell Cycle; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Naphthoquinones; Nitrogen Mustard Compounds; Stromal Cells; Survivin; Toll-Like Receptor 9; Vidarabine | 2014 |
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Germany; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Office Visits; Prednisone; Prospective Studies; Registries; Rituximab; Vidarabine | 2015 |
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Bone Marrow Cells; Cells, Cultured; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Primary Cell Culture; Stromal Cells; Time Factors; Vidarabine | 2014 |
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; CD40 Ligand; Cell Hypoxia; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrogen Mustard Compounds; Nitrophenols; Oxygen; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Vidarabine | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Leukaemia cutis after starting bendamustine: cause or coincidence?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Erythema Nodosum; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Rituximab; Skin; Vidarabine | 2015 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2016 |
Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
Topics: Adult; Aged; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2017 |
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2019 |
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Rituximab; Survival Rate; Vidarabine | 2019 |
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Predictive Value of Tests; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2019 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Topics: Antigens, CD; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Receptors, Cell Surface; Vidarabine | 2020 |
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy.
Topics: Bendamustine Hydrochloride; DNA Methylation; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Suppressor Protein p53; Vidarabine | 2020 |
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2022 |
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2023 |
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Topics: B-Cell Maturation Antigen; Bendamustine Hydrochloride; Cell- and Tissue-Based Therapy; Cyclophosphamide; Humans; Immunotherapy, Adoptive; Multiple Myeloma; Receptors, Chimeric Antigen | 2023 |